NEW YORK (GenomeWeb News) – TriLink BioTechnologies today said that it has received a Phase II Small Business Innovation Research grant of around $725,000 to continue its studies of DNA ligase.
The San Diego-based firm said that it will use the funds to continue its research on chemically modified components as a means of enhancing ligation fidelity in a variety of applications including SNP detection, proximity ligation, and sequencing by ligation.
TriLink CEO Richard Hogrefe said in a statement that the firm is "confident we will soon offer a number of novel ligation products to compliment our CleanAmp PCR line of products."
TriLink said the latest award is its fourth Phase II grant and will be provided through February 2012.